• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生物活性化合物的结构研究。23. 多羟基化2-苯基苯并噻唑的合成及其与染料木黄酮和槲皮素的细胞毒性和药理特性比较。

Structural studies on bioactive compounds. 23. Synthesis of polyhydroxylated 2-phenylbenzothiazoles and a comparison of their cytotoxicities and pharmacological properties with genistein and quercetin.

作者信息

Stevens M F, McCall C J, Lelieveld P, Alexander P, Richter A, Davies D E

机构信息

Department of Pharmaceutical Sciences, University of Nottingham, U.K.

出版信息

J Med Chem. 1994 May 27;37(11):1689-95. doi: 10.1021/jm00037a020.

DOI:10.1021/jm00037a020
PMID:8201603
Abstract

A series of polyhydroxylated 2-phenylbenzothiazoles 3 has been prepared by demethylation of the precursor methoxylated 2-phenylbenzothiazoles 9. The key step in the construction of the benzothiazole nucleus involves a Jacobson cyclization of methoxylated thiobenzanilides 8. The target compounds inhibit WiDr human colon tumor cells and MCF-7 human mammary tumor cells in vitro with IC50 values in the low micromolar range, but the activity against MCF-7 cells is not related to estrogen receptor-binding affinity. None of the compounds showed selective cytotoxicity against Abelson virus-transformed ANN-1 cells encoded with the pp120gag-abl tyrosine kinase compared with the parental 3T3 line. Compounds were only marginally inhibitory to the EGF receptor-associated protein tyrosine kinase from a membrane preparation of A431 cells. The most active compound was 4,6-dihydroxy-2-(4-hydroxyphenyl)benzothiazole (3b) which has the same overall hydroxyl substitution pattern as genistein (1a). The compounds were weakly cytotoxic for an EGF receptor, overexpressing cell line HN5, but when tested for differential toxicity against the EGF receptor tyrosine kinase or the PDGF receptor tyrosine kinase in a standard mitogenesis assay utilizing human fibroblasts, no discrimination was observed. In this assay, the compounds inhibited DNA synthesis when added to cells during S phase. This suggests that inhibition could not be interpreted in terms of tyrosine kinase inactivation but more likely as a relatively broad specificity for the ATP-binding domain of other kinases such as thymidine kinase.

摘要

通过对前体甲氧基化的2-苯基苯并噻唑9进行脱甲基反应,制备了一系列多羟基化的2-苯基苯并噻唑3。构建苯并噻唑核的关键步骤涉及甲氧基化硫代苯甲酰苯胺8的雅各布森环化反应。目标化合物在体外对WiDr人结肠肿瘤细胞和MCF-7人乳腺肿瘤细胞具有抑制作用,IC50值在低微摩尔范围内,但对MCF-7细胞的活性与雌激素受体结合亲和力无关。与亲本3T3细胞系相比,没有一种化合物对由pp120gag-abl酪氨酸激酶编码的阿贝尔森病毒转化的ANN-1细胞表现出选择性细胞毒性。化合物对来自A431细胞膜制剂的表皮生长因子(EGF)受体相关蛋白酪氨酸激酶仅有微弱的抑制作用。活性最强的化合物是4,6-二羟基-2-(4-羟基苯基)苯并噻唑(3b),其总体羟基取代模式与染料木黄酮(1a)相同。这些化合物对过表达EGF受体的细胞系HN5具有微弱的细胞毒性,但在利用人成纤维细胞的标准促细胞分裂试验中检测其对EGF受体酪氨酸激酶或血小板衍生生长因子(PDGF)受体酪氨酸激酶的差异毒性时,未观察到区分作用。在该试验中,当在S期将化合物添加到细胞中时,它们会抑制DNA合成。这表明抑制作用不能用酪氨酸激酶失活来解释,而更可能是对其他激酶(如胸苷激酶)的ATP结合域具有相对广泛的特异性。

相似文献

1
Structural studies on bioactive compounds. 23. Synthesis of polyhydroxylated 2-phenylbenzothiazoles and a comparison of their cytotoxicities and pharmacological properties with genistein and quercetin.生物活性化合物的结构研究。23. 多羟基化2-苯基苯并噻唑的合成及其与染料木黄酮和槲皮素的细胞毒性和药理特性比较。
J Med Chem. 1994 May 27;37(11):1689-95. doi: 10.1021/jm00037a020.
2
Mechanisms of action in NIH-3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity.表皮生长因子受体酪氨酸激酶活性抑制剂染料木黄酮在NIH-3T3细胞中的作用机制
Biochem Pharmacol. 1990 Jan 1;39(1):187-93. doi: 10.1016/0006-2952(90)90664-7.
3
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.酪氨酸激酶抑制剂。14. 4-[(3-溴苯基)氨基]-6-(甲氨基)-吡啶并[3,4-d]嘧啶(PD 158780)的甲氨基取代衍生物的构效关系,PD 158780是表皮生长因子家族受体酪氨酸激酶活性的一种强效且特异性抑制剂。
J Med Chem. 1998 Feb 26;41(5):742-51. doi: 10.1021/jm970641d.
4
Synthesis and biological evaluation of a series of flavones designed as inhibitors of protein tyrosine kinases.一系列被设计为蛋白酪氨酸激酶抑制剂的黄酮类化合物的合成与生物学评价。
Anticancer Drug Des. 1992 Oct;7(5):365-84.
5
Use and specificity of genistein as inhibitor of protein-tyrosine kinases.染料木黄酮作为蛋白酪氨酸激酶抑制剂的用途及特异性。
Methods Enzymol. 1991;201:362-70. doi: 10.1016/0076-6879(91)01032-w.
6
Inhibitors of protein tyrosine phosphorylation reduce the proliferation of two human glioma cell lines.蛋白质酪氨酸磷酸化抑制剂可降低两种人类胶质瘤细胞系的增殖。
Neurosurgery. 1996 Jan;38(1):108-13; discussion 113-4. doi: 10.1097/00006123-199601000-00026.
7
Inhibition of tyrosine kinase activity decreases expression of surfactant protein A in a human lung adenocarcinoma cell line independent of epidermal growth factor receptor.酪氨酸激酶活性的抑制降低了人肺腺癌细胞系中表面活性蛋白A的表达,且该过程不依赖于表皮生长因子受体。
Biochim Biophys Acta. 1997 Mar 1;1355(3):218-30. doi: 10.1016/s0167-4889(96)00134-6.
8
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.可溶性2-取代氨基吡啶并[2,3-d]嘧啶-7-基脲。针对选定酪氨酸激酶的构效关系以及体外和体内抗癌活性的探索。
J Med Chem. 2001 Jun 7;44(12):1915-26. doi: 10.1021/jm0004291.
9
Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.酪氨酸激酶抑制剂。6. N-和3-取代的2,2'-二硒代双(1H-吲哚)对蛋白酪氨酸激酶抑制作用的构效关系以及与选定硫类似物的体外和体内比较研究。
J Med Chem. 1997 Feb 14;40(4):413-26. doi: 10.1021/jm960689b.
10
Structural studies on bioactive compounds. 40.(1) Synthesis and biological properties of fluoro-, methoxyl-, and amino-substituted 3-phenyl-4H-1-benzopyran-4-ones and a comparison of their antitumor activities with the activities of related 2-phenylbenzothiazoles.生物活性化合物的结构研究。40.(1)氟代、甲氧基和氨基取代的3-苯基-4H-1-苯并吡喃-4-酮的合成及生物学性质,以及它们与相关2-苯基苯并噻唑的抗肿瘤活性比较。
J Med Chem. 2006 Jun 29;49(13):3973-81. doi: 10.1021/jm060359j.

引用本文的文献

1
Transformation of Amides to Thioamides Using an Efficient and Novel Thiating Reagent.酰胺到硫代酰胺的转化:一种高效新颖的硫代试剂的应用。
Molecules. 2022 Nov 27;27(23):8275. doi: 10.3390/molecules27238275.
2
Design, synthesis, molecular modeling and biological evaluation of novel Benzoxazole-Benzamide conjugates a 2-Thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers.新型苯并恶唑-苯甲酰胺化合物的设计、合成、分子模拟及生物评价:以 2-硫乙酰胺为连接基的潜在抗增殖剂、VEGFR-2 抑制剂和凋亡诱导剂。
J Enzyme Inhib Med Chem. 2022 Dec;37(1):1587-1599. doi: 10.1080/14756366.2022.2081844.
3
Synthesis, antiproliferative and antitrypanosomal activities, and DNA binding of novel 6-amidino-2-arylbenzothiazoles.
新型 6-脒基-2-芳基苯并噻唑的合成、抗增殖和抗锥虫活性及 DNA 结合。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1952-1967. doi: 10.1080/14756366.2021.1959572.
4
Halothane, a novel solvent for the preparation of liposomes containing 2-4'-amino-3'-methylphenyl benzothiazole (AMPB), an anticancer drug: a technical note.氟烷,一种用于制备含有抗癌药物2-4'-氨基-3'-甲基苯基苯并噻唑(AMPB)的脂质体的新型溶剂:技术说明。
AAPS PharmSciTech. 2003;4(2):E20. doi: 10.1208/pt040220.
5
Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445).对2-(4-氨基苯基)苯并噻唑(CJM 126,NSC 34445)获得性耐药的机制
Br J Cancer. 2000 Jul;83(2):270-7. doi: 10.1054/bjoc.2000.1231.
6
Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals.多酚类植物化学物质对线粒体质子F0F1-ATP酶/ATP合酶的抑制作用。
Br J Pharmacol. 2000 Jul;130(5):1115-23. doi: 10.1038/sj.bjp.0703397.
7
Activation of LA-N-2 cell phospholipase D by amyloid beta protein (25-35).淀粉样β蛋白(25 - 35)对LA - N - 2细胞磷脂酶D的激活作用。
Neurochem Res. 1998 Oct;23(10):1225-32. doi: 10.1023/a:1020731813973.
8
Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo.2-(4-氨基苯基)苯并噻唑对人卵巢癌细胞体内外生长的影响
Br J Cancer. 1998 Aug;78(4):421-9. doi: 10.1038/bjc.1998.510.
9
2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity.2-(4-氨基苯基)苯并噻唑:具有体外抗肿瘤活性选择性特征的新型药物。
Br J Cancer. 1998 Mar;77(5):745-52. doi: 10.1038/bjc.1998.122.